NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Collaborating Centre for Chronic Conditions (UK). Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians (UK); 2008. (NICE Clinical Guidelines, No. 66.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Type 2 Diabetes

Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update).

Show details

References

1.
National Institute for Health and Clinical Excellence. Guidelines manual. London: NICE; 2006.
2.
International Diabetes Federation. Definition and diagnosis of diabetes mellitus and immediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organisation; 2006.
3.
Department of Health. Health survey for England 2004. London: DH; 2005.
4.
International Diabetes Federation. Diabetes atlas. Brussels: IDF; 2006.
5.
Morgan CL, Currie CJ, Peters JR. Relationship between diabetes and mortality: a population study using record linkage. Diabetes Care. 2000;23(8):1103–1107. [PubMed: 10937505]
6.
British National Formulary for Children. UK: BMJ Publishing Group, Ltd and RPS Publishing; 2007. http://bnfc​.org/bnfc.
7.
National Collaborating Centre for Chronic Conditions. Type 2 diabetes: methodology pack. London: NCC-CC; 2006.
8.
Healthcare Commission. Managing diabetes: improving services for people with diabetes. London: Commission for Healthcare Audit and Inspection; 2007.
9.
Christensen NK, Williams P, Pfister R. Cost savings and clinical effectiveness of an extension service diabetes program. Diabetes Spectrum. 2004;17(3):171–175.
10.
Mortimer D, Kelly J. Economic evaluation of the good life club intervention for diabetes self-management. Australian Journal of Primary Health. 2006;12(1):91–100.
11.
Connor H, Annan F, Bunn E, et al. The implementation of nutritional advice for people with diabetes. Diabetic Medicine. 2003;20(10):786–807. [PubMed: 14510859]
12.
National Institute for Health and Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children (CG43) London: NICE; 2006. [PubMed: 22497033]
13.
Li Z, Hong K, Saltsman P, et al. Long-term efficacy of soy-based meal replacements vs an individualized diet plan in obese type II DM patients: Relative effects on weight loss, metabolic parameters, and C-reactive protein. European Journal of Clinical Nutrition. 2005;59(3):411–418. [PubMed: 15674301]
14.
Barnard ND, Cohen J, Jenkins DJA, et al. A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care. 2006;29(8):1777–1783. [PubMed: 16873779]
15.
Brinkworth GD, Noakes M. Long-term effects of advice to consume a high-protein, low-fat diet, rather than a conventional weight-loss diet, in obese adults with type 2 diabetes: one-year follow-up of a randomised trial. Diabetologia. 2004;47(10):1677–1686. [PubMed: 15480538]
16.
Daly ME, Paisey R. Short-term effects of severe dietary carbohydrate-restriction advice in Type 2 diabetes – a randomized controlled trial. Diabetic Medicine. 2006;23(1):15–20. [PubMed: 16409560]
17.
Redmon JB, Susan KR, Kristell PR, et al. One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: A randomized trial. Diabetes Care. 2003;26(9):2505. [PubMed: 12941710]
18.
Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Annals of Internal Medicine. 2004;140(10):778–785. [PubMed: 15148064]
19.
The Diabetes and Nutrition Study Group of the Spanish Diabetes Association (GSEDNu) Diabetes nutrition and complications trial: adherence to the ADA nutritional recommendations, targets of metabolic control, and onset of diabetes complications. A 7-year, prospective, population-based, observational multicenter study. Journal of Diabetes & its Complications. 2006;20(6):361–366. [PubMed: 17070439]
20.
Van ST, Van de Laar FA, Van Leeuwe JF, et al. The dieting dilemma in patients with newly diagnosed type 2 diabetes: does dietary restraint predict weight gain 4 years after diagnosis? Health Psychology. 2007;26(1):105–112. [PubMed: 17209703]
21.
Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069–1078. [PubMed: 11375373]
22.
Rubin RR, Ciechanowski P, Egede LE, et al. Recognizing and treating depression in patients with diabetes. Current Diabetes Reports. 2004;4(2):119–125. [PubMed: 15035972]
23.
de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: a meta-analysis. Psychosomatic Medicine. 2001;63(4):619–630. [PubMed: 11485116]
24.
Lin EH, Katon W, Von KM, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care. 2004;27(9):2154–2160. [PubMed: 15333477]
25.
Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care. 2002;25(3):464–470. [PubMed: 11874931]
26.
National Institute for Health and Clinical Excellence. Diagnosis and management of type 1 diabetes in children, young people and adults (CG15) London: NICE; 2004.
27.
National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care (CG23) London: NICE; 2004.
28.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal. 2000;321(7258):405–412. [PMC free article: PMC27454] [PubMed: 10938048]
29.
Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Annals of Internal Medicine. 2004;141(6):421–431. [PubMed: 15381515]
30.
Gerstein HC, Pogue J. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia. 2005;48(9):1749–1755. [PubMed: 16059716]
31.
Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103(22):2668–2673. [PubMed: 11390335]
32.
Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ. The association between diabetes related medical costs and glycemic control: A retrospective analysis. Cost Effectiveness & Resource Allocation. 2006;4:1. [PMC free article: PMC1369002] [PubMed: 16412255]
33.
Clarke PM, Gray AM, Briggs A, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) Diabetologia. 2005;48(5):868–877. [PubMed: 15834550]
34.
Clarke P, Gray A, Adler A, et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS no. 51) Diabetologia. 2001;44(3):298–304. [PubMed: 11317659]
35.
ACCORD. ACCORD Study Announcement. www​.accordtrial.org. Date of message: 6 February 2008.
36.
Sarol JN, Nicodemus NA, Tan KM, et al. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966–2004) Current Medical Research & Opinion. 2005;21(2):173–184. [PubMed: 15801988]
37.
Welschen LM, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care. 2005;28(6):1510–1517. [PubMed: 15920083]
38.
Welschen LM, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Cochrane Database of Systematic Reviews. 2005;(2):CD005060. [PubMed: 15846742]
39.
Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Current Medical Research & Opinion. 2006;22(4):671–681. [PubMed: 16684428]
40.
Farmer A, Wade A, French DP, et al. The DiGEM trial protocol: a randomised controlled trial to determine the effect on glycaemic control of different strategies of blood glucose self-monitoring in people with type 2 diabetes. BMC Family Practice. 2005;6(25) [PMC free article: PMC1185530] [PubMed: 15960852]
41.
Moreland EC, Volkening LK, Lawlor MT, et al. Use of a blood glucose monitoring manual to enhance monitoring adherence in adults with diabetes: a randomized controlled trial. Archives of Internal Medicine. 2006;166(6):689–695. [PubMed: 16567610]
42.
Siebolds M, Gaedeke O, Schwedes U, et al. Self-monitoring of blood glucose – psychological aspects relevant to changes in HbA1c in type 2 diabetic patients treated with diet or diet plus oral antidiabetic medication. Patient Education & Counseling. 2006;62(1):104–110. [PubMed: 16159705]
43.
Karter AJ, Chan J, Parker MM, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care. 2006;29(8) [PMC free article: PMC2213628] [PubMed: 16873776]
44.
Martin S, Schneider B, Heinemann L, et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia. 2006;49(2):271–278. [PubMed: 16362814]
45.
Wen L, Parchman ML, Linn WD, et al. Association between self-monitoring of blood glucose and glycemic control in patients with type 2 diabetes mellitus. American Journal of Health-System Pharmacy. 2004;61(22):2401–2405. [PubMed: 15581263]
46.
Davis WA, Bruce DG, Davis TM. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care. 2006;29(8):1764–1770. [PubMed: 16873777]
47.
Schutt M, Kern W, Krause U, et al. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Experimental & Clinical Endocrinology & Diabetes. 2006;114(7):384–388. [PubMed: 16915542]
48.
Kalergis M, Nadeau J, Pacaud D, et al. Accuracy and reliability of reporting self-monitoring of blood glucose results in adults with type 1 and type 2 diabetes. Canadian Journal of Diabetes. 2006;30(3):241–247.
49.
Lawton J, Peel E, Douglas M, et al. ‘Urine testing is a waste of time’: newly diagnosed type 2 diabetes patients’ perceptions of self-monitoring. Diabetic Medicine. 2004;21(9):1045–1048. [PubMed: 15317613]
50.
Peel E, Parry O, Douglas M, et al. Blood glucose self-monitoring in non-insulin-treated type 2 diabetes: a qualitative study of patients’ perspectives. British Journal of General Practice. 2004;54(500):183–188. [PMC free article: PMC1314828] [PubMed: 15006123]
51.
Palmer AJ, Dinneen S, Gavin JR III, et al. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Current Medical Research & Opinion. 2006;22(5):861–872. [PubMed: 16709308]
52.
Gray A, Clarke P, Farmer A, et al. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: Cost analysis (UKPDS 63) British Medical Journal. 2002;325(7369):860–863. [PMC free article: PMC129631] [PubMed: 12386035]
53.
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UKPDS Group. Lancet. 1998;352(9131):837–853. [PubMed: 9742976]
54.
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine. 2006;355(23):2427–2443. [PubMed: 17145742]
55.
UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44(11):1249–1258. [PubMed: 7589820]
56.
Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2005;(3):CD002966. [PubMed: 16034881]
57.
Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2003;(2):CD002967. [PubMed: 12804446]
58.
Cryer DR, Nicholas SP, Henry DH, et al. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care. 2005;28(3):539–543. [PubMed: 15735184]
59.
Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Journal of Clinical Endocrinology & Metabolism. 2004;89(12):6068–6076. [PubMed: 15579760]
60.
Derosa G, Franzetti I, Gadaleta G, et al. Metabolic variations with oral antidiabetic drugs in patients with type 2 diabetes: comparison between glimepiride and metformin. Diabetes, Nutrition & Metabolism –Clinical & Experimental. 2004;17(3):143–150. [PubMed: 15334791]
61.
Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Current Medical Research & Opinion. 2005;21(12):2029–2035. [PubMed: 16368054]
62.
Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clinical Therapeutics. 2005;27(10):1548–1561. [PubMed: 16330291]
63.
Marre M, Van GL, Usadel KH, et al. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes, Obesity & Metabolism. 2002;4(3):177–186. [PubMed: 12047396]
64.
Kvapil M, Swatko A, Hilberg C, et al. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes, Obesity & Metabolism. 2006;8(1):39–48. [PubMed: 16367881]
65.
Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clinical Therapeutics. 2003;25(2):515–529. [PubMed: 12749511]
66.
Fujioka K, Brazg RL, Raz I, et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes, Obesity & Metabolism. 2005;7(1):28–39. [PubMed: 15642073]
67.
Blonde L, Dailey G, Jabbour SA, et al. Gastrointerstinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research & Opinion. 2006;20(4):565–572. [PubMed: 15119994]
68.
Mohammad F, Fenna I, Leong K, et al. Audit of metformin sustained release (SR) in patients intolerant of immediate release metformin. Diabetic Medicine. 2006;23(Suppl 2):111.
69.
Nagle A, Brake J, Hopkins M, Glucophage SR, et al. Can it really make a difference? Diabetic Medicine. 2006;23(Suppl 2):110.
70.
Thomas Z, Phillips SM, Hogan D, et al. The tolerability of prolonged-release metformin (Glucophage SR) in previously metformin intolerant patients – review of local experience. Diabetic Medicine. 2006;23(Suppl 2):111.
71.
Yousseif A, Roberts S, Malik S, et al. Patient reported side effects and compliance with Glucophage SR. Diabetic Medicine. 2006;23(Suppl 2):111.
72.
Palmer AJ, Roze S, Lammert M, et al. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Current Medical Research & Opinion. 2004;20(Suppl 1):S41–S51. [PubMed: 15324515]
73.
Salas M, Ward A, Caro J. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. Clinical Therapeutics. 2002;24(10):1690–1705. [PubMed: 12462297]
74.
Ward AJ, Salas M, Caro JJ, Owens D. Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime costs of complications in the UK. Cost Effectiveness & Resource Allocation. 2004;2:2. [PMC free article: PMC406422] [PubMed: 15086954]
75.
Caro JJ, Salas M, Ward AJ, et al. Combination therapy for type 2 diabetes: what are the potential health and cost implications in Canada? Canadian Journal of Diabetes. 2003;27(1):33–41.
76.
Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care. 2003;26(8):2231–2237. [PubMed: 12882841]
77.
Tong PC, Chow CC, Jorgensen LN, et al. The contribution of metformin to glycaemic control in patients with type 2 diabetes mellitus receiving combination therapy with insulin. Diabetes Research & Clinical Practice. 2002;57(2):93–98. [PubMed: 12062853]
78.
Inukai K, Watanabe M, Nakashima Y, et al. Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diabetes Research & Clinical Practice. 2005;68(3):250–257. [PubMed: 15936468]
79.
Jibran R, Suliman MI, Qureshi F, et al. Safety and efficay of repaglinide compared with glibenclamide in the management of type 2 diabetic Pakistani patients. Pakistan Journal of Medical Sciences. 2006;22(4):385–390.
80.
Saloranta C, Hershon K, Ball M, et al. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. Journal of Clinical Endocrinology & Metabolism. 2002;87(9):4171–4176. [PubMed: 12213867]
81.
Bengel FM, Abletshauser C, Neverve J, et al. Effects of nateglinide on myocardial microvascular reactivity in type 2 diabetes mellitus: a randomized study using positron emission tomography. Diabetic Medicine. 2005;22(2):158–163. [PubMed: 15660732]
82.
Moses RG, Gomis R, Frandsen KB, et al. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care. 2001;24(1):11–15. [PubMed: 11194214]
83.
Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care. 2004;27(6):1265–1270. [PubMed: 15161773]
84.
Derosa G, Mugellini A, Ciccarelli L, et al. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clinical Therapeutics. 2003;25(2):472–484. [PubMed: 12749508]
85.
Madsbad S, Kilhovd B, Lager I, et al. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study. Diabetic Medicine. 2001;18(5):395–401. [PubMed: 11472451]
86.
Esposito K, Giugliano D, Nappo F, et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110(2):214–219. [PubMed: 15197140]
87.
Furlong NJ, Hulme SA, O’Brien SV, et al. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with type 2 diabetes inadequately controlled with oral hypoglycaemic agents. Diabetic Medicine. 2003;20(11):935–941. [PubMed: 14632720]
88.
Raskin P, Klaff L, McGill J, et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care. 2003;26(7):2063–2068. [PubMed: 12832314]
89.
Gerich J, Raskin P, Jean LL, et al. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care. 2005;28(9):2093–2099. [PubMed: 16123472]
90.
Ristic S, ColloberMaugeais C, Pecher E, et al. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Medicine. 2006;23(7):757–762. [PMC free article: PMC1569640] [PubMed: 16842480]
91.
Horton ES, Foley JE, Shen SG, et al. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. Current Medical Research & Opinion. 2004;20(6):883–889. [PubMed: 15200747]
92.
Dashora UK, Sibal L, Ashwell SG, et al. Insulin glargine in combination with nateglinide in people with type 2 diabetes: a randomized placebo-controlled trial. Diabetic Medicine. 2007;24(4):344–349. [PubMed: 17298589]
93.
Schernthaner G, Grimaldi A, Di MU, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. European Journal of Clinical Investigation. 2004;34(8):535–542. [PubMed: 15305887]
94.
Lu CH, Chang CC, Chuang LM, et al. Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients. Diabetes, Obesity & Metabolism. 2006;8(2):184–191. [PubMed: 16448522]
95.
Charpentier G, Fleury F, Kabir M, et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabetic Medicine. 2001;18(10):828–834. [PubMed: 11678974]
96.
Forst T, Eriksson JW, Strotmann HJ, et al. Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes. Experimental & Clinical Endocrinology & Diabetes. 2003;111(2):97–103. [PubMed: 12746761]
97.
Wright AD, Cull CA, Macleod KM, et al. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis (UKPDS 73) Journal of Diabetes & its Complications. 2006;20(6):395–401. [PubMed: 17070446]
98.
Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside randomised controlled trial (UKPDS 41) British Medical Journal. 2000;320(7246):1373–1378. [PMC free article: PMC27380] [PubMed: 10818026]
99.
Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2005;(2):CD003639. [PubMed: 15846673]
100.
Ko GTC, Tsang CC, Ng CW, et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clinical Drug Investigation. 2001;21(6):401–408.
101.
Goke B. German Pioglitazone Study Group. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Treatments in Endocrinology. 2002;1(5):329–336. [PubMed: 15832486]
102.
Feinbock C, Luger A, Klingler A, et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Diabetes, Nutrition & Metabolism - Clinical & Experimental. 2003;16(4):214–221.
103.
Hwu CM, Ho LT, Fuh MM, et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Diabetes Research & Clinical Practice. 2003;60(2):111–118. [PubMed: 12706319]
104.
Phillips P, Karrasch J, Scott R, et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Diabetes Care. 2003;26(2):269–273. [PubMed: 12547847]
105.
Bachmann W, Petzinna D, Raptis SA, et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clinical Drug Investigation. 2003;23(10):679–686. [PubMed: 17535083]
106.
Lin BJ, Wu HP, Huang HS, et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Journal of Diabetes & its Complications. 2003;17(4):179–185. [PubMed: 12810240]
107.
Segal P, Eliahou HE, Petzinna D, et al. Effects on blood pressure of the a-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clinical Drug Investigation. 2005;25(9):589–595. [PubMed: 17532703]
108.
White TJ, Vanderplas A, Chang E, et al. The costs of non-adherence to oral antihyperglycemic medication in individuals with diabetes mellitus and concomitant diabetes mellitus and cardiovascular disease in a managed care environment. Disease Management and Health Outcomes. 2004;12(3):181–188.
109.
Quilici S, Chancellor J, Maclaine G, et al. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden. International Journal of Clinical Practice. 2005;59(10):1143–1152. [PubMed: 16178980]
110.
Huang ES, Shook M, Jin L, et al. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care. 2006;29(2):259–264. [PMC free article: PMC2292131] [PubMed: 16443870]
111.
Johnson JA, Simpson SH, Toth EL, et al. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabetic Medicine. 2005;22(4):497–502. [PubMed: 15787679]
112.
Evans JMM, Ogston SA, EmslieSmith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: A comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49(5):930–936. [PubMed: 16525843]
113.
National Institute for Health and Clinical Excellence. Glitazones in the treatment of type 2 diabetes (Review of TA9 and TA21) (TA63) London: NICE; 2003.
114.
European Medicines Agency. 2007. www​.emea.europa.eu.
115.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine. 2007;356(24):2457–2471. [PubMed: 17517853]
116.
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. New England Journal of Medicine. 2007;357(1):28–38. [PubMed: 17551159]
117.
Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. The Journal of the American Medical Association. 2007;298(10):1180–1188. [PubMed: 17848652]
118.
Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Annals of Internal Medicine. 2007;147(8):578–581. [PubMed: 17679700]
119.
Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis [see comment] The Journal of the American Medical Association. 2007;298(10):1189–1195. [PubMed: 17848653]
120.
Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129–1136. [PubMed: 17905165]
121.
GlaxoSmithKline. Coronary heart disease outcomes in patients receiving antidiabetic agents. Uxbridge, Middlesex: GlaxoSmithKline; 2008.
122.
Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2007;(3):CD006063. [PubMed: 17636824]
123.
Derosa G, Gaddi AV, Piccinni MN, et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes, Obesity & Metabolism. 2006;8(2):197–205. [PubMed: 16448524]
124.
Rosenstock J, Goldstein BJ, Vinik AI, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes, Obesity & Metabolism. 2006;8(1):49–57. [PubMed: 16367882]
125.
Raskin P, McGill J, Saad MF, et al. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabetic Medicine. 2004;21(4):329–335. [PubMed: 15049934]
126.
Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. Journal of Hypertension. 2006;24(10):2047–2055. [PubMed: 16957566]
127.
Vongthavaravat V, Wajchenberg BL, Waitman JN, et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Current Medical Research & Opinion. 2002;18(8):456–461. [PubMed: 12564655]
128.
St John SM, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25(11):2058–2064. [PubMed: 12401757]
129.
Hanefeld M, Patwardhan R, Jones NP, et al. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutrition Metabolism & Cardiovascular Diseases. 2007;17(1):13–23. [PubMed: 17174222]
130.
Kerenyi Z, Samer H, James R, et al. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Research & Clinical Practice. 2004;63(3):213–223. [PubMed: 14757293]
131.
Derosa G, Gaddi AV, Piccinni MN, et al. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy. 2005;25(5):637–645. [PubMed: 15899724]
132.
Baksi A, James RE, Zhou B, et al. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. Acta Diabetologica. 2004;41(2):63–69. [PubMed: 15224207]
133.
Derosa G, D’Angelo A, Ragonesi PD, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Internal Medicine Journal. 2007;37(2):79–86. [PubMed: 17229249]
134.
Rosenstock J, Rood J, Cobitz A, et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes, Obesity & Metabolism. 2006;8(6):650–660. [PubMed: 17026489]
135.
Stewart MW, Cirkel DT, Furuseth K, et al. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled type 2 diabetes. Diabetic Medicine. 2006;23(10):1069–1078. [PubMed: 16978370]
136.
Home PD, Jones NP, Pocock SJ, et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine. 2007;24(6):626–634. [PMC free article: PMC1974811] [PubMed: 17517066]
137.
Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24(7):1226–1232. [PubMed: 11423507]
138.
Home PD, Bailey CJ, Donaldson J, et al. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with type 2 diabetes. Diabetic Medicine. 2007;24(6):618–625. [PMC free article: PMC1974817] [PubMed: 17403121]
139.
Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29(3):554–559. [PubMed: 16505505]
140.
Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care. 2007;30(4):795–800. [PubMed: 17259481]
141.
Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2006;(4):CD006060. [PubMed: 17054272]
142.
Dormandy JA. PROactive study. Lancet. 2006;367(9405):26–27.
143.
Yudkin JS, Freemantle N. PROactive study. Lancet. 2006;367(3504):24–25. [PubMed: 16399143]
144.
PROactive Study Executive Committee and Data and Safety Monitoring Committee. PROactive study. Lancet. 2006;367(9515):982. [PubMed: 16564353]
145.
Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clinical Therapeutics. 2005;27(5):554–567. [PubMed: 15978304]
146.
Davidson JA, Perez A, Zhang J. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes, Obesity & Metabolism. 2006;8(2):164–174. [PubMed: 16448520]
147.
Raz I, Stranks S, Filipczak R, et al. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Clinical Therapeutics. 2005;27(9):1432–1443. [PubMed: 16291416]
148.
Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia. 2005;48(6):1093–1104. [PubMed: 15889234]
149.
Jain R, Osei K, Kupfer S, et al. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy. 2006;26(10):1388–1395. [PubMed: 16999648]
150.
Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. Journal of the American College of Cardiology. 2007;49(17):1772–1780. [PubMed: 17466227]
151.
Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. The Journal of the American Medical Association. 2006;296(21):2572–2581. [PubMed: 17101640]
152.
Wilcox R, Bousser MG, Betteridge DJ, et al. effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) Stroke. 2007;38(3):865–873. [PubMed: 17290029]
153.
Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Research & Clinical Practice. 2007;76(2):279–289. [PubMed: 17055103]
154.
Czoski-Murray C, Warren E, Chilcott J, et al. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation (structured abstract) Health Technology Assessment. 2004;8(13) [PubMed: 15038907]
155.
National Institute for Health and Clinical Excellence. Diabetes (type 2) – pioglitazone (replaced by TA63) (TA21) London: NICE; 2001.
156.
Beale S, Bagust A, Shearer AT, et al. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics. 2006;24(Suppl 1):21–34. [PubMed: 16800160]
157.
Tilden DP, Mariz S, O’BryanTear G, et al. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics. 2007;25(1):39–54. [PubMed: 17192117]
158.
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289. [PubMed: 16214598]
159.
Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635. [PubMed: 15504997]
160.
DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100. [PubMed: 15855572]
161.
Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083–1091. [PubMed: 15855571]
162.
Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes, Obesity & Metabolism. 2006;8(4):436–447. [PubMed: 16776751]
163.
Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technology & Therapeutics. 2005;7(3):467–477. [PubMed: 15929678]
164.
Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine. 2005;143(8):559–569. [PubMed: 16230722]
165.
Secnik BK, Matza LS, Oglesby A, et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health & Quality of Life Outcomes. 2006;4(80) [PMC free article: PMC1634743] [PubMed: 17034640]
166.
Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50(2):259–267. [PubMed: 17160407]
167.
Zinman B, Hoogwerf BJ, Duran GS, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine. 2007;146(7):477–485. [PubMed: 17404349]
168.
European Medicines Agency. EPARs for authorised medicinal products for human use. [Last accessed on: 19 January 2008]. Available from: www​.emea.europa.eu.
169.
Ray JA, Boye KS, Yurgin N, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Current Medical Research & Opinion. 2007;23(3):609–622. [PubMed: 17355742]
170.
Goudswaard AN, Furlong NJ, Rutten GE, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2004;(4):CD003418. [PubMed: 15495054]
171.
Kokic SB. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. Collegium Antropologicum. 2003;27(1):181–187. [PubMed: 12974145]
172.
Olsson PO, Lindstrom T. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes. Diabetes & Metabolism. 2002;28(4:Pt 1):272–277. [PubMed: 12442064]
173.
Altuntas Y, Ozen B, Ozturk B, et al. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. Diabetes, Obesity & Metabolism. 2003;5(6):371–378. [PubMed: 14617222]
174.
Kabadi MU, Kabadi UM. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. Annals of Pharmacotherapy. 2003;37(11):1572–1576. [PubMed: 14565810]
175.
Zargar AH, Masoodi SR, Laway BA, et al. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure. Journal of the Association of Physicians of India. 2002;50(5):641–646. [PubMed: 12186116]
176.
Douek IF, Allen SE, Ewings P, et al. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabetic Medicine. 2005;22(5):634–640. [PubMed: 15842521]
177.
Goudswaard AN, Stolk RP, Zuithoff P, et al. Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. Journal of Family Practice. 2004;53(5):393–399. [PubMed: 15125825]
178.
Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28(2):254–259. [PubMed: 15677775]
179.
Stehouwer MH, DeVries JH, Lumeij JA, et al. Combined bedtime insulin – daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypo-glycaemia rate – a randomised trial. Diabetes/Metabolism Research and Reviews. 2003;19(2):148–152. [PubMed: 12673783]
180.
Lechleitner M, Roden M, Haehling E, et al. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus. Wiener Klinische Wochenschrift. 2005;117(17):593–598. [PubMed: 16395988]
181.
Drummond M, O’Brien B, Stoddart G, Torrance G. Methods for economic evaluation of health care programmes. 2nd edn. Oxford: Oxford University Press; 2003.
182.
Christiansen JS, Vaz JA, Metelko Z. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes, Obesity & Metabolism. 2003;5(6):446–454. [PubMed: 14617231]
183.
Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. Journal of Diabetes & its Complications. 2003;17(6):307–313. [PubMed: 14583174]
184.
Ceriello A, Del PS, Bue VJ, et al. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. Journal of Diabetes & its Complications. 2007;21(1):20–27. [PubMed: 17189870]
185.
Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews. 2006;(2):CD003287. [PubMed: 16625575]
186.
Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients [erratum appears in Diabetic Medicine. 2002 Sep;19(9):797] Diabetic Medicine. 2002;19(5):393–399. [PubMed: 12027927]
187.
Boehm BO, Vaz JA, Brondsted L, et al. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. European Journal of Internal Medicine. 2004;15(8):496–502. [PubMed: 15668084]
188.
Abrahamian H, Ludvik B, Schernthaner G, et al. Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study) Hormone & Metabolic Research. 2005;37(11):684–689. [PubMed: 16308837]
189.
Schernthaner G, Kopp HP, Ristic S, et al. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. Hormone & Metabolic Research. 2004;36(3):188–193. [PubMed: 15057674]
190.
Ligthelm RJ, Mouritzen U, Lynggaard H, et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Experimental & Clinical Endocrinology & Diabetes. 2006;114(9):511–519. [PubMed: 17115349]
191.
Joshi SR, Kalra S, Badgandi M, et al. Designer insulins regimens in clinical practice – pilot multicenter Indian study. Journal of the Association of Physicians of India. 2005;53(Sept):775–779. [PubMed: 16334621]
192.
Davies M, Storms F, Shutler S. Initiation of Insulin Glargine in type 2 patients with suboptimal glycaemic control on twice-daily premix insulin: results from the AT.LANTUS trial. Diabetologia. 2004;47(Suppl 1):319.
193.
National Institute for Clinical Excellence. The clinical effectiveness and cost effectiveness of long acting insulin analogues for diabetes (TA53) London: NICE; 2002.
194.
Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28(4):950–955. [PubMed: 15793205]
195.
Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2007;(2):CD005613. [PubMed: 17443605]
196.
Yki JH, Kauppinen MR, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49(3):442–451. [PubMed: 16456680]
197.
Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28(7):1568–1573. [PubMed: 15983302]
198.
Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260–265. [PubMed: 15677776]
199.
Eliaschewitz FG, Calvo C, Valbuena H, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research. 2006;37(4):495–501. [PubMed: 16715577]
200.
Rosskamp R. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients. Diabetic Medicine. 2003;20(7):545–551. [PubMed: 12823235]
201.
Malone JK, Kerr LF, Campaigne BN, et al. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clinical Therapeutics. 2004;26(12):2034–2044. [PubMed: 15823767]
202.
Malone JK, Bai S, Campaigne BN, et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabetic Medicine. 2005;22(4):374–381. [PubMed: 15787659]
203.
Jacober SJ, Scism BJ, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes, Obesity & Metabolism. 2006;8(4):448–455. [PubMed: 16776752]
204.
Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Experimental & Clinical Endocrinology & Diabetes. 2006;114(9):527–532. [PubMed: 17115351]
205.
Kazda C, Hulstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. Journal of Diabetes & its Complications. 2006;20(3):145–152. [PubMed: 16632233]
206.
Pan CY, Sinnassamy P, Chung KD, et al. Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research & Clinical Practice. 2007;76(1):111–118. [PubMed: 17011662]
207.
Raskin PR, Hollander PA, Lewin A, et al. Basal insulin or premix analogue therapy in type 2 diabetes patients. European Journal of Internal Medicine. 2007;18(1):56–62. [PubMed: 17223044]
208.
Yokoyama H, Tada J, Kamikawa F, et al. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research & Clinical Practice. 2006;73(1):35–40. [PubMed: 16513202]
209.
Standl E, Maxeiner S, Raptis S, et al. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Hormone & Metabolic Research. 2006;38(3):172–177. [PubMed: 16673208]
210.
Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabetic Medicine. 2006;23(7):736–742. [PubMed: 16842477]
211.
Fritsche A, Schweitzer MA, Haring HU, et al. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine. 2003;138(12):952–959. [PubMed: 12809451]
212.
Massi BM, Humburg E, Dressler A, et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone & Metabolic Research. 2003;35(3):189–196. [PubMed: 12734781]
213.
Riddle MC, Rosenstock J, Gerich J, et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086. [PubMed: 14578243]
214.
Rosenstock J, Schwartz SL, Clark CM Jr, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24(4):631–636. [PubMed: 11315821]
215.
Warren E, Weatherley-Jones E, Chilcott J, et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technology Assessment. 2004;8(45):iii, 1–57. [PubMed: 15525480]
216.
McEwan P, Poole CD, Telow T, et al. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Current Medical Research & Opinion. 2007;23(1):S7–S19.
217.
National Institute for Health and Clinical Excellence. The clinical effectiveness and cost effectiveness of insulin pump therapy (TA57) London: NICE; 2003.
218.
Little RR, Rohilfing CL, Wiedmeyer HM, et al. The National Glycohaemoglobin Standardization Program (NGSP): a five-year progress report. Clinical Chemistry. 2001;47:1985–1992. [PubMed: 11673367]
219.
Coscelli C. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Research & Clinical Practice. 1995;28(3):173–177. [PubMed: 8529495]
220.
Fox C, McKinnon C, Wall A, et al. Ability to handle, and patient preference for, insulin delivery devices in visually impaired patients with type 2 diabetes. Practical Diabetes International. 2002;19(4):104–107.
221.
Kadiri A, Chraibi A, Marouan F, et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Research & Clinical Practice. 1998;41(1):15–23. [PubMed: 9768368]
222.
Korytkowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clinical Therapeutics. 2003;25(11):2836–2848. [PubMed: 14693308]
223.
Shelmet J. Preference and resource utilization in elderly patients: InnoLet versus vial/syringe. Diabetes Research & Clinical Practice. 2004;63(1):27–35. [PubMed: 14693410]
224.
Stockl K, Ory C, Vanderplas A, et al. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Current Medical Research & Opinion. 2007;23(1):133–146. [PubMed: 17257475]
225.
Asakura T, Seino H. Assessment of dose selection attributes with audible notification in insulin pen devices. Diabetes Technology & Therapeutics. 2005;7(4):620–626. [PubMed: 16120036]
226.
Turner R, Holman R, Stratton I, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38) British Medical Journal. 1998;317:703–713. [PMC free article: PMC28659] [PubMed: 9732337]
227.
Sibal L, Law HN, Gebbie J, et al. Cardiovascular risk factors predicting the development of distal symmetrical polyneuropathy in people with type 1 diabetes: A 9-year follow-up study. Annals of the New York Academy of Sciences. 2006;1084:304–318. [PubMed: 17151310]
228.
Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. Journal of the American Society of Nephrology. 2005;16(10):3027–3037. [PubMed: 16120823]
229.
Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. Journal of the American Society of Nephrology. 2005;16(7):2170–2179. [PubMed: 15930097]
230.
Matthews DR, Stratton IM, Aldington SJ, et al. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus (UKPDS 69) Archives of Opthalmology. 2004;122(11):1631–1640. [PubMed: 15534123]
231.
Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Archives of Internal Medicine. 2003;163(13):1555–1565. [PubMed: 12860578]
232.
Estacio RO, Coll JR, Tran ZV, et al. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. American Journal of Hypertension. 2006;19(12):1241–1248. [PubMed: 17161769]
233.
Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney International. 2002;61(3):1086–1097. [PubMed: 11849464]
234.
Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Archives of Internal Medicine. 2005;165(12):1410–1419. [PubMed: 15983291]
235.
Torffvit O, Agardh CD. A blood pressure cut-off level identified for renal failure, but not for macro-vascular complications in type 2 diabetes: a 10-year observation study. Hormone & Metabolic Research. 2002;34(1):32–35. [PubMed: 11832999]
236.
Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database of Systematic Reviews. 2005;(4):CD004136. [PubMed: 16235351]
237.
Strippoli GF, Bonifati C, Craig M, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews. 2006;(4):CD006257. [PubMed: 17054288]
238.
Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366(9502):2026–2033. [PubMed: 16338452]
239.
Mann JF, Gerstein HC, Yi QL, et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. American Journal of Kidney Diseases. 2003;42(5):936–942. [PubMed: 14582037]
240.
Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. Journal of the American Society of Nephrology. 2003;14(3):641–647. [PubMed: 12595499]
241.
Bosch J. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation. 2005;112(9):1339–1346. [PubMed: 16129815]
242.
Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. New England Journal of Medicine. 2004;351(19):1952–1961. [PubMed: 15516696]
243.
Sengul AM, Altuntas Y, Kurklu A, et al. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Research & Clinical Practice. 2006;71(2):210–219. [PubMed: 16112244]
244.
Dalla VM, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina) Diabetes, Nutrition & Metabolism – Clinical & Experimental. 2004;17(5):259–266. [PubMed: 16295047]
245.
Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. American Journal of Hypertension. 2002;15(12):1042–1049. [PubMed: 12460699]
246.
Ruggenenti P, Perna A, Ganeva M, et al. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. Journal of the American Society of Nephrology. 2006;17(12):3472–3481. [PubMed: 17082240]
247.
Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Archives of Internal Medicine. 2005;165(12):1401–1409. [PubMed: 15983290]
248.
Fernandez R, Puig JG, Rodriguez PJ, et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. Journal of Human Hypertension. 2001;15(12):849–856. [PubMed: 11773987]
249.
Holzgreve H, Nakov R, Beck K, et al. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. American Journal of Hypertension. 2003;16(5:Pt 1):381–386. [PubMed: 12745200]
250.
Derosa G, Cicero AF, Gaddi A, et al. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. Journal of Cardiovascular Pharmacology. 2005;45(6):599–604. [PubMed: 15897788]
251.
Derosa G, Cicero AF, Bertone G, et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clinical Therapeutics. 2004;26(8):1228–1236. [PubMed: 15476904]
252.
Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106(6):672–678. [PubMed: 12163426]
253.
Appel GB, Radhakrishnan J, Avram MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003;26(5):1402–1407. [PubMed: 12716796]
254.
Remuzzi G, Ruggenenti P, Perna A, et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. Journal of the American Society of Nephrology. 2004;15(12):3117–3125. [PubMed: 15579515]
255.
Andersen S, Bröchner-Mortensen J, Parving HH, et al. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2003;26(12):3296–3302. [PubMed: 14633817]
256.
Lindholm LH, Ibsen H. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):1004–1010. [PubMed: 11937179]
257.
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine. 2001;345(12):851–860. [PubMed: 11565517]
258.
Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. Journal of Hypertension. 2006;24(11):2163–2168. [PubMed: 17053536]
259.
Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. The Journal of the American Medical Association. 2003;290(21):2805–2816. [PubMed: 14657064]
260.
Bakris GL, Fonseca V. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. The Journal of the American Medical Association. 2004;292(18):2227–2236. [PubMed: 15536109]
261.
Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. The Journal of the American Medical Association. 2003;289(16):2073–2082. [PubMed: 12709465]
262.
Dahlöf B. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906. [PubMed: 16154016]
263.
Beard SM, Gaffney L, Backhouse ME. An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus (structured abstract) Journal of Medical Economics. 2001;4:199–205.
264.
Schadlich PK, Brecht JG, Rangoonwala B, et al. Cost effectiveness of ramipril in patients at high risk for cardiovascular events: economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective. Pharmacoeconomics. 2004;22(15):955–973. [PubMed: 15449961]
265.
Gray A, Clarke P, Raikou M, et al. An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54) Diabetic Medicine. 2001;18(6):438–444. [PubMed: 11472461]
266.
Palmer AJ, Annemans L, Roze S, et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. Journal of Human Hypertension. 2004;18:733–738. [PubMed: 15116142]
267.
Rodby RA, Chiou CF, Borenstein J, et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clinical Therapeutics. 2003;25(7):2102–2119. [PubMed: 12946554]
268.
Coyle D, Rodby RA. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. Canadian Journal of Cardiology. 2004;20(1):71–79. [PubMed: 14968145]
269.
Vora J, Carides G, Robinson P. Effects of losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom. Current Therapeutic Research, Clinical & Experimental. 2005;66(6):475–485. [PMC free article: PMC3965974] [PubMed: 24678070]
270.
Smith DG, Nguyen AB, Peak CN, et al. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria. Journal of Managed Care Pharmacy. 2004;10(1):26–32. [PubMed: 14720103]
271.
International currency rates. [Last accessed on: 13 March 2007]. Available from: Financial Times.
272.
National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care (CG34) London: NICE; 2006.
273.
Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine. 1998;339(4):229–234. [PubMed: 9673301]
274.
Eddy DM, Schlessinger L. Validation of the archimedes diabetes model. Diabetes Care. 2003;26(11):3102–3110. [PubMed: 14578246]
275.
Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabetic Medicine. 2004;21(3):238–245. [PubMed: 15008833]
276.
Stephens JW, Ambler G, Vallance P, et al. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? European Journal of Cardiovascular Prevention and Rehabilitation. 2004;11(6):521–528. [PubMed: 15580065]
277.
Guzder RN, Gatling W, Mullee MA, et al. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabetic Medicine. 2005;22(5):554–562. [PubMed: 15842509]
278.
Coleman RL, Stevens RJ, Renakaran R, et al. Framington, SCORE and DECODE do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care. 2007;30(5):1292–1293. [PubMed: 17290036]
279.
Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56) Clinical Science. 2001;101(6):671–679. [PubMed: 11724655]
280.
Tuomilehto J, Rastenyte D. Epidemiology of macrovascular disease and hypertension in diabetes mellitus, International textbook of diabetes mellitus. 2nd edn . Chichester: John Wiley; 1997. pp. 1559–1583.
281.
Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278. [PubMed: 16214597]
282.
Vijan S, Hayward RA. American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Annals of Internal Medicine. 2004;140(8):650–658. [PubMed: 15096337]
283.
National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events in patients at increased risk of developing cardiovascular disease or those with established cardiovascular disease (TA94) London: NICE; 2006.
284.
National Institute for Health and Clinical Excellence. Ezetimibe for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia (TA132) London: NICE; 2007.
285.
Insull W, Kafonek S, Goldner D, et al. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. American Journal of Cardiology. 2001;87(5):554–559. [PubMed: 11230838]
286.
van Venrooij FV, van de Ree MA, Bots ML, et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2002;25(7):1211–1216. [PubMed: 12087021]
287.
Miller M, Dobs A, Yuan Z, et al. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. Current Medical Research & Opinion. 2004;20(7):1087–1094. [PubMed: 15265253]
288.
Berne C, Siewert DA. URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovascular Diabetology. 2005;4:7. [PMC free article: PMC1166567] [PubMed: 15935095]
289.
Colhoun HM, Betteridge DJ, Durrington PN, et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS) Diabetologia. 2005;48(12):2482–2485. [PubMed: 16284747]
290.
Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA) Diabetes Care. 2005;28(5):1151–1157. [PubMed: 15855581]
291.
Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29(6):1220–1226. [PubMed: 16731999]
292.
Steiner G, Hamsten A, Hosking J, et al. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357(9260):905–910. [PubMed: 11289345]
293.
Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS) Circulation. 2003;107(13):1733–1737. [PubMed: 12665498]
294.
Keech A, Simes R, Barter P, et al. Effects of long–term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet. 2005;366(9500):1849–1861. [PubMed: 16310551]
295.
Derosa G, Cicero AE, Bertone G, et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clinical Therapeutics. 2004;26(10):1599–1607. [PubMed: 15598476]
296.
Athyros VG, Papageorgiou VV, Athyrou DS, et al. Atorvastatin and micronized fenofibrate alone and in combination, in type-2 diabetes mellitus with combined hyperlipidemia. Atherosclerosis. 2002;3(2):70. [PubMed: 12087019]
297.
Durrington PN, Tuomilehto J, Hamann A, et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Research & Clinical Practice. 2004;64(2):137–151. [PubMed: 15063607]
298.
Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. Journal of the American College of Cardiology. 2006;48(2):396–401. [PubMed: 16843192]
299.
Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Archives of Internal Medicine. 2002;162(22):2597–2604. [PubMed: 12456232]
300.
Ashraf R, Amir K, Shaikh AR. Comparison between duration dependent effects of simvastatin and gemfibrozil on dyslipidemia in patients with type 2 diabetes. Journal of the Pakistan Medical Association. 2005;55(8):324–327. [PubMed: 16164158]
301.
Schweitzer M, Tessier D, Vlahos WD, et al. A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis. 2002;162(1):201–210. [PubMed: 11947915]
302.
Wagner AM, Jorba O, Bonet R, et al. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. Journal of Clinical Endocrinology & Metabolism. 2003;88(7):3212–3217. [PubMed: 12843167]
303.
Feher MD, Langley-Hawthorne CE, Byrne CD. Cost-outcome benefits of fibrate therapy in type 2 diabetes. British Journal of Diabetes & Vascular Disease. 2003;3(2):124–130.
304.
Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. The Journal of the American Medical Association. 2000;284(10):1263–1270. [PubMed: 10979113]
305.
Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Archives of Internal Medicine. 2002;162(14):1568–1576. [PubMed: 12123399]
306.
Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. The Journal of the American Medical Association. 1990;264(6):723–726. [PubMed: 2374275]
307.
Tsalamandris C, Panagiotopoulos S, Sinha A, et al. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. Journal of Cardiovascular Risk. 1994;1(3):231–239. [PubMed: 7621303]
308.
Armstrong EP, Zachry WM III, Malone DC. Cost-effectiveness analysis of simvastatin and lovastatin/extended-release niacin to achieve LDL and HDL goal using NHANES data. Journal of Managed Care Pharmacy. 2004;10(3):251–258. [PubMed: 15228376]
309.
Olson BM, Malone DC, Armstrong EP. Modeling the cost-effectiveness of doubling atorvastatin’s dose versus adding niacin ER. Formulary. 2001;36(10):730–746.
310.
Roze S, Wierzbicki AS, Liens D, et al. Cost-effectiveness of adding prolonged-release nicotinic acid in statin-treated patients who achieve LDL cholesterol goals but remain at risk due to low HDL cholesterol: a UK-based economic evaluation. British Journal of Cardiology. 2006;13(6):411–418.
311.
Farmer A, Montori V, Dinneen S, et al. Fish oil in people with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2001;(3):CD003205. [PubMed: 11687050]
312.
Hartweg J, Farmer AJ, Holman RR, et al. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia. 2007;50(2):250–258. [PubMed: 17119918]
313.
Jain S, Gaiha M, Bhattacharjee J, et al. Effects of low-dose omega-3 fatty acid substitution in type-2 diabetes mellitus with special reference to oxidative stress – a prospective preliminary study. Journal of the Association of Physicians of India. 2002;50(Aug):1028–1033. [PubMed: 12421024]
314.
Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. American Journal of Clinical Nutrition. 2002;76(5):1007–1015. [PubMed: 12399272]
315.
Pedersen H, Petersen M, Major-Pedersen A, et al. Influence of fish oil supplementation on in vivo and in vitro oxidation resistance of low-density lipoprotein in type 2 diabetes. European Journal of Clinical Nutrition. 2003;57(5):713–720. [PubMed: 12771973]
316.
Petersen M, Pedersen H, Major-Pedersen A, et al. Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in type 2 diabetic patients. Diabetes Care. 2002;25(10):1704–1708. [PubMed: 12351465]
317.
Dunstan DW, Mori TA, Puddey IB, et al. Exercise and fish intake: effects on serum lipids and glycemic control for type 2 diabetics. Cardiology Review. 1998;15(8):34–37.
318.
Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. British Medical Journal. 2006;332(7544):752–760. [PMC free article: PMC1420708] [PubMed: 16565093]
319.
Wood D, Durrington P, McInnes G, et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart. 1998;80(Suppl 2):1S–29S.
320.
McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A. Clinical guidelines and evidence review for type 2 diabetes: management of blood glucose. Sheffield: School of Health and Related Research; 2001.
321.
National Institute for Health and Clinical Excellence. Clopidogrel and modified release dipyridamole in the prevention of occlusive vascular events (TA90) London: NICE; 2005.
322.
Khajehdehi P, Roozbeh J, Mostafavi H. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology & Nephrology. 2002;36(2):145–148. [PubMed: 12028688]
323.
Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26(12):3264–3272. [PubMed: 14633812]
324.
Neri Serneri GG, Coccheri S, Marubini E, et al. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID study. European Heart Journal. 2004;25(20):1845–1852. [PubMed: 15474700]
325.
Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–337. [PubMed: 15276392]
326.
Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. American Journal of Cardiology. 2002;90(6):625–628. [PubMed: 12231089]
327.
Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine. 2001;345(7):494–502. [PubMed: 11519503]
328.
Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine. 2006;354(16):1706–1717. [PubMed: 16531616]
329.
Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. The Journal of the American Medical Association. 2002;288(19):2411–2420. [PubMed: 12435254]
330.
Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–533. [PubMed: 11520521]
331.
Jonsson B, Hansson L, Stalhammar NO. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine. 2003;253(4):472–480. [PubMed: 12653877]
332.
National Institute for Health and Clinical Excellence. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80) London: NICE; 2004.
333.
Weintraub WS, Mahoney EM, Lamy A, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. Journal of the American College of Cardiology. 2005;45(6):838–845. [PubMed: 15766816]
334.
Ringborg A, Lindgren P, Jonsson B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. European Journal of Health Economics. 2005;6(4):354–362. [PubMed: 16267654]
335.
Cowper PA, Udayakumar K, Sketch MH Jr, et al. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. Journal of the American College of Cardiology. 2005;45(3):369–376. [PubMed: 15680714]
336.
Harvey JN. Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Current Opinion in Nephrology & Hypertension. 2003;12(3):317–322. [PubMed: 12698072]
337.
Banerjee S, Ghosh US, Saha SJ. Role of GFR estimation in assessment of the status of nephropathy in type 2 diabetes mellitus. Journal of the Association of Physicians of India. 2005;53:181–4. [PubMed: 15926598]
338.
Baskar V, Venugopal H, Holland MR, et al. Clinical utility of estimated glomerular filtration rates in predicting renal risk in a district diabetes population. Diabetic Medicine. 2006;23(10):1057–1060. [PubMed: 16978368]
339.
Cortes SL, Martinez RH, Hernandez JL, et al. Utility of the Dipstick Micraltest II in the screening of microalbuminuria of diabetes mellitus type 2 and essential hypertension. Revista de Investigacion Clinica. 2006;58(3):190–197. [PubMed: 16958293]
340.
Incerti J, Zelmanovitz T, Camargo JL, et al. Evaluation of tests for microalbuminuria screening in patients with diabetes. Nephrology Dialysis Transplantation. 2005;20(11):2402–2407. [PubMed: 16105865]
341.
MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004;27(1):195–200. [PubMed: 14693989]
342.
Middleton RJ, Foley RN, Hegarty J, et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrology Dialysis Transplantation. 2006;21(1):88–92. [PubMed: 16221715]
343.
Parikh CR, Fischer MJ, Estacio R, et al. Rapid microalbuminuria screening in type 2 diabetes mellitus: simplified approach with Micral test strips and specific gravity [erratum appears in Nephrol Dial Transplant 2004;19(9):2425] Nephrology Dialysis Transplantation. 2004;19(7):1881–1885. [PubMed: 15161951]
344.
Poggio ED, Wang X, Greene T, et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. Journal of the American Society of Nephrology. 2005;16(2):459–466. [PubMed: 15615823]
345.
Rigalleau V, Lasseur C, Perlemoine C, et al. A simplified Cockcroft-Gault formula to improve the prediction of the glomerular filtration rate in diabetic patients. Diabetes & Metabolism. 2006;32(1):56–62. [PubMed: 16523187]
346.
Younis N, Broadbent DM, Vora JP, et al. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet. 2003;361(9353):195–200. [PubMed: 12547541]
347.
UK National Screening Committee. Essential elements in developing a diabetic retinopathy screening programme, Workbook. 1–79. Vol. 4. Available from: UK National Screening Committee.
348.
Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. New England Journal of Medicine. 1992;326(19):1250–1256. [PubMed: 1560801]
349.
Sindrup SH, Gram LF, Skjold T, et al. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. British Journal of Clinical Pharmacology. 1990;30(5):683–691. [PMC free article: PMC1368167] [PubMed: 2271367]
350.
Sindrup SH, Tuxen C. Lack of effect of mianserin on the symptoms of diabetic neuropathy. European Journal of Clinical Pharmacology. 1992;43(3):251–255. [PubMed: 1425887]
351.
Morello CM, Leckband SG, Stoner CP, et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Archives of Internal Medicine. 1999;159(16):1931–1937. [PubMed: 10493324]
352.
Jose VM, Bhansali A, Hota D, et al. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabetic Medicine. 2007;24(4):377–383. [PubMed: 17335465]
353.
Kvinesdal B, Molin J, Froland A, et al. Imipramine treatment of painful diabetic neuropathy. The Journal of the American Medical Association. 1984;251(13):1727–1730. [PubMed: 6366276]
354.
Max MB, Kishore KR, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 1991;45(1):3–9. [PubMed: 1861872]
355.
Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37(4):589–596. [PubMed: 2436092]
356.
Sindrup SH, Ejlertsen B. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. European Journal of Clinical Pharmacology. 1989;37(2):151–153. [PubMed: 2792168]
357.
Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. Journal of Palliative Medicine. 2006;9(1):29–40. [PubMed: 16430342]
358.
Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Medicine. 2005;6(5):346–356. [PubMed: 16266355]
359.
Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1–2):109–118. [PubMed: 15927394]
360.
Hardy T, Sachson R, Shen S, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care. 2007;30(1):21–26. [PubMed: 17192327]
361.
Raskin J, Wang F, Pritchett YL, et al. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Medicine. 2006;7(5):373–385. [PubMed: 17014595]
362.
Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411–1420. [PubMed: 17060567]
363.
Wernicke JF, Raskin J, Rosen A, et al. Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial. Current Therapeutic Research, Clinical & Experimental. 2006;67(5):283–304. [PMC free article: PMC3966007] [PubMed: 24678103]
364.
Gomez-Perez FJ, PerezMonteverde A, Nascimento O, et al. Gabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical response. British Journal of Diabetes & Vascular Disease. 2004;4(3):173–178.
365.
Gorson KC, Schott C, Herman R, et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. Journal of Neurology, Neurosurgery, and Psychiatry. 1999;66(2):251–252. [PMC free article: PMC1736215] [PubMed: 10071116]
366.
Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. The Journal of the American Medical Association. 1998;280(21):1831–1836. [PubMed: 9846777]
367.
Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. Journal of Clinical Neuromuscular Disease. 2001;3(2):53–62. [PubMed: 19078655]
368.
Lesser H, Sharma U, Lamoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63(11):2104–2110. [PubMed: 15596757]
369.
Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. Journal of Pain. 2005;6(4):253–260. [PubMed: 15820913]
370.
Rosenstock J, Tuchman M, Lamoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110(3):628–638. [PubMed: 15288403]
371.
Rull JA, Quibrera R, Gonzalez MH, et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia. 1969;5(4):215–218. [PubMed: 4902717]
372.
Wilton TD. Tegretol in the treatment of diabetic neuropathy. South African Medical Journal. 1974;48(20):869–872. [PubMed: 4597907]
373.
Gomez-Perez FJ, Choza R, Rios JM, et al. Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Archives of Medical Research. 1996;27(4):525–529. [PubMed: 8987189]
374.
Beydoun A, Kobetz SA, Carrazana EJ. Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. Clinical Journal of Pain. 2004;20(3):174–178. [PubMed: 15100593]
375.
Dogra S, Beydoun S, Mazzola J, et al. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. European Journal of Pain. 2005;9(5):543–554. [PubMed: 16139183]
376.
Grosskopf J, Mazzola J, Wan Y, et al. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica. 2006;114(3):177–180. [PubMed: 16911345]
377.
Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. Journal of Pain. 2006;7(2):119–128. [PubMed: 16459277]
378.
Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. American Family Physician. 2005;71(3):483–490. [PubMed: 15712623]
379.
Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. Journal of Pain. 2006;7(6):399–407. [PubMed: 16750796]
380.
National Institute for Health and Clinical Excellence. Type 2 diabetes: prevention and management of foot problems (CG10) London: NICE; 2004.
381.
Braun AP. Domperidone in the treatment of symptoms of delayed gastric emptying in diabetic patients. Advances in Therapy. 1989;6(2):51–62.
382.
Samsom M. Effects of oral erythromycin on fasting and postprandial antroduodenal motility in patients with type I diabetes, measured with an ambulatory manometric technique. Diabetes Care. 1997;20(2):129–134. [PubMed: 9118759]
383.
Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. New England Journal of Medicine. 1990;322(15):1028–1031. [PubMed: 2320062]
384.
McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6(5):463–467. [PubMed: 6400707]
385.
Ricci DA, Saltzman MB, Meyer C, et al. Effect of metoclopramide in diabetic gastroparesis. Journal of Clinical Gastroenterology. 1985;7(1):25–32. [PubMed: 3884697]
386.
Farup CE, Leidy NK, Murray M, et al. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care. 1998;21(10):1699–1706. [PubMed: 9773734]
387.
Erbas T, Varoglu E, Erbas B, et al. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care. 1993;16(11):1511–1514. [PubMed: 8299441]
388.
Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. American Journal of Gastroenterology. 1999;94(5):1230–1234. [PubMed: 10235199]
389.
McCulloch DK, Campbell IW, Wu FC, et al. The prevalence of diabetic impotence. Diabetologia. 1980;18(4):279–283. [PubMed: 7418954]
390.
Price DE, Gingell JC, Gepi AS, et al. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabetic Medicine. 1998;15(10):821–825. [PubMed: 9796881]
391.
Rendell MS, Rajfer J. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. The Journal of the American Medical Association. 1999;281(5):421–426. [PubMed: 9952201]
392.
Boulton AJM, Selam JL, Sweeney M, et al. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia. 2001;44(10):1296–1301. [PubMed: 11692178]
393.
Saenz de Tejada I, Anglin G, Knight JR, et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care. 2002;25(12):2159–2164. [PubMed: 12453954]
394.
Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003;26(3):777–783. [PubMed: 12610037]
395.
Stuckey BGA, Jadzinsky MN, Murphy LJ, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care. 2003;26(2):279–284. [PubMed: 12547849]
396.
Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. Journal of Diabetes & its Complications. 2004;18(4):205–210. [PubMed: 15207837]
397.
Ishii N, Nagao K, Fujikawa K, et al. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. International Journal of Urology. 2006;13(8):1066–1072. [PubMed: 16903931]
398.
Ziegler D, Merfort F, van Ahlen, et al. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. Journal of Sexual Medicine. 2006;3(5):883–891. [PubMed: 16942532]
399.
Buvat J, van Ahlen, Schmitt H, et al. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries. Journal of Sexual Medicine. 2006;3(3):512–520. [PubMed: 16681477]
400.
Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value in Health. 2003;6:9–17. [PubMed: 12535234]
401.
Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) Diabetologia. 2004;47(10):1747–1759. [PubMed: 15517152]
402.
Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65) Diabetic Medicine. 2003;20(6):442–450. [PubMed: 12786677]
403.
Curtis L, Netten A. Unit costs of health and social care 2006. Canterbury: Personal Social Services Research Unit; 2006.
404.
Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. British Journal of General Practice. 2007;57(539):455–460. [PMC free article: PMC2078170] [PubMed: 17550670]
405.
Scottish Medicines Consortium. Glasgow. New product assessment form – exenatide. Personal communication. 2006.
406.
Davies Melanie. Personal communication. May 31, 2007.
407.
Warren E. The cost-effectiveness of long-acting insulin analogue, insulin glargine. Sheffield: ScHARR; Aug 16, 2002.
408.
Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Current Medical Research & Opinion. 2006;22(8):1523–1534. [PubMed: 16870077]
409.
Contributed poster presentations. Value in Health. 2006;9(3):A24–A173.
410.
Rowlett R. How many? A dictionary of units of measurement. 2001.
411.
Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technology Assessment. 2005;9(26):1–iv. [PubMed: 16014203]
412.
GlaxoSmithKline. Rosiglitazone maleate ZM2006/00207/00(meta-analysis)1–8. GlaxoSmithKline; Jun 27, 2006.
413.
Food and Drug Administration. Avandia (rosiglitazone maleate) FDA; 2007. NDA21-071 supplement 022.
414.
National Institute for Health and Clinical Excellence. Management of type 2 diabetes – management of blood pressure and blood lipids (Guideline H) London: NICE; 2002.
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

Bookshelf ID: NBK53887

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.7M)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...